OSRC
MCID: OST159
MIFTS: 66

Osteogenic Sarcoma (OSRC)

Categories: Bone diseases, Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Osteogenic Sarcoma

MalaCards integrated aliases for Osteogenic Sarcoma:

Name: Osteogenic Sarcoma 58 12 77 54 60 76 15
Osteosarcoma 58 12 54 60 76 38 30 13 56 6 45 15 41 17 74
Neoplasms, Bone Tissue 45 74
Osrc 58 76
Osteosarcoma, Somatic 58
Bone Tissue Neoplasm 12
Osteosarcoma of Bone 74
Osteosarcoma; Osrc 58
Skeletal Sarcoma 12
Osteoid Sarcoma 12
Bone Sarcoma 74

Characteristics:

Orphanet epidemiological data:

60
osteosarcoma
Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Childhood;

OMIM:

58
Inheritance:
somatic mutation

Miscellaneous:
increased incidence of osteosarcoma in retinoblastoma cases with rb1 mutations
peak frequency in adolescence


HPO:

33
osteogenic sarcoma:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 60  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:3347
OMIM 58 259500
KEGG 38 H00036
NCIt 51 C9145
SNOMED-CT 69 21708004
MESH via Orphanet 46 D012516
ICD10 via Orphanet 35 C41.9
UMLS via Orphanet 75 C0029463
Orphanet 60 ORPHA668
MedGen 43 C0029463

Summaries for Osteogenic Sarcoma

NIH Rare Diseases : 54 Osteosarcoma is the most common type of bone cancer. The average age at diagnosis is 15. Boys and girls have a similar incidence of this tumor until late adolescence, at which time boys are more commonly affected. In rare cases, osteosarcoma occurs in adults. Although osteosarcoma tends to occur in the larger bones, such as the shin (near the knee), thigh (near the knee) and upper arm (near the shoulder), it can occur in any bone.A number of variants of osteosarcoma exist, including conventional types (osteoblastic, chondroblastic, and fibroblastic), telangiectatic, multifocal, parosteal, and periosteal. The cause of osteosarcoma is not known. In some cases, it runs in families, and at least one gene has been linked to increased risk. Treatment varies from person to person and may include surgery, chemotherapy, radiation therapy, and samarium.

MalaCards based summary : Osteogenic Sarcoma, also known as osteosarcoma, is related to lung cancer susceptibility 3 and li-fraumeni syndrome 2. An important gene associated with Osteogenic Sarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Human T-cell leukemia virus 1 infection and p53 Signaling. The drugs Zoledronic Acid and Denosumab have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and kidney, and related phenotypes are osteolysis and abnormality of the femoral metaphysis

Disease Ontology : 12 A bone cancer that is located in bone that has material basis in cells of mesenchymal origin.

UniProtKB/Swiss-Prot : 76 Osteogenic sarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones.

Wikipedia : 77 An osteosarcoma (OS) or osteogenic sarcoma (OGS) is a cancerous tumor in a bone. Specifically, it is an... more...

Description from OMIM: 259500

Related Diseases for Osteogenic Sarcoma

Diseases related to Osteogenic Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 463)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 31.6 AKT1 FENDRR HOTAIR TP53 TUG1
2 li-fraumeni syndrome 2 30.8 CHEK2 TP53
3 glioma 30.8 HOTAIR MIR140 NEAT1 TP53 UCA1
4 squamous cell carcinoma 30.6 AKT1 CHEK2 HOTAIR NEAT1 RB1 TP53
5 myeloma, multiple 30.5 AKT1 HOTAIR TP53 TUG1 UCA1
6 nasopharyngeal carcinoma 30.5 AKT1 HOTAIR NEAT1 TP53
7 breast cancer 30.4 AKT1 BCAR4 CHEK2 FOXC2-AS1 HOTAIR LINC00901
8 prostate cancer 30.4 AKT1 CHEK2 FENDRR HOTAIR NEAT1 RB1
9 glioblastoma 30.4 AKT1 HOTAIR RB1 TP53 TUG1 TUSC7
10 hepatocellular carcinoma 30.3 AKT1 HOTAIR NEAT1 NNT-AS1 RB1 SNHG12
11 thyroid cancer 30.3 AKT1 HOTAIR NEAT1 TP53 UCA1
12 atypical teratoid rhabdoid tumor 30.3 ATRX HOTAIR TP53
13 small cell cancer of the lung 30.2 AKT1 HOTAIR RB1 TP53 TUG1
14 colorectal cancer 30.2 AKT1 BCAR4 CHEK2 HOTAIR MIR140 NEAT1
15 cholangiocarcinoma 30.2 AKT1 NEAT1 TP53 TUG1 UCA1
16 lung cancer 30.1 AKT1 BCAR4 CHEK2 FENDRR HOTAIR MIR140
17 leukemia, acute myeloid 30.1 AKT1 HOTAIR TP53 TUG1 TUSC7 UCA1
18 thyroid cancer, nonmedullary, 1 30.1 HOTAIR NEAT1 SNHG12
19 cervical cancer 30.1 AKT1 BCAR4 EWSAT1 HOTAIR NEAT1 NNT-AS1
20 aging 30.0 AKT1 CHEK2 TP53
21 ovarian cancer 30.0 AKT1 CHEK2 HOTAIR MIR140 NEAT1 NNT-AS1
22 multifocal osteogenic sarcoma 12.4
23 telangiectatic osteogenic sarcoma 12.4
24 periosteal osteogenic sarcoma 12.4
25 small cell osteogenic sarcoma 12.4
26 kidney osteogenic sarcoma 12.4
27 synchronous multifocal osteogenic sarcoma 12.4
28 intracortical osteogenic sarcoma 12.3
29 adult extraosseous osteosarcoma 12.3
30 bone osteosarcoma 12.3
31 conventional central osteosarcoma 12.2
32 pediatric osteosarcoma 12.2
33 peripheral osteosarcoma 12.2
34 childhood parosteal osteogenic sarcoma 12.2
35 mediastinal osteogenic sarcoma 12.2
36 hepatic osteogenic sarcoma 12.2
37 asynchronous multifocal osteogenic sarcoma 12.2
38 childhood extraosseous osteosarcoma 12.2
39 osteosarcoma arising in bone paget's disease 12.1
40 childhood intracortical osteosarcoma 12.0
41 metachronous osteosarcoma of the bone 12.0
42 central nervous system osteosarcoma 12.0
43 oslam syndrome 11.9
44 bone cancer 11.8
45 juxtacortical osteosarcoma 11.6
46 sarcoma 11.4
47 li-fraumeni syndrome 11.4
48 rapadilino syndrome 11.4
49 hereditary multiple osteochondromas 11.4
50 primary bone cancer 11.3

Graphical network of the top 20 diseases related to Osteogenic Sarcoma:



Diseases related to Osteogenic Sarcoma

Symptoms & Phenotypes for Osteogenic Sarcoma

Human phenotypes related to Osteogenic Sarcoma:

60 33 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteolysis 60 33 hallmark (90%) Very frequent (99-80%) HP:0002797
2 abnormality of the femoral metaphysis 60 33 hallmark (90%) Very frequent (99-80%) HP:0006489
3 joint swelling 60 33 frequent (33%) Frequent (79-30%) HP:0001386
4 pain 60 33 frequent (33%) Frequent (79-30%) HP:0012531
5 increased lactate dehydrogenase activity 60 33 frequent (33%) Frequent (79-30%) HP:0025435
6 elevated alkaline phosphatase 60 33 frequent (33%) Frequent (79-30%) HP:0003155
7 abnormality of the tibial metaphysis 60 33 frequent (33%) Frequent (79-30%) HP:0006491
8 fever 60 33 very rare (1%) Very rare (<4-1%) HP:0001945
9 weight loss 60 33 very rare (1%) Very rare (<4-1%) HP:0001824
10 pathologic fracture 60 33 very rare (1%) Very rare (<4-1%) HP:0002756
11 abnormality of metabolism/homeostasis 33 HP:0001939
12 abnormality of the metaphysis 60 Frequent (79-30%)
13 retinoblastoma 33 HP:0009919
14 osteosarcoma 33 HP:0002669
15 abnormal lactate dehydrogenase activity 60 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
osteogenic sarcoma

Skeletal:
bone destruction and mineralized soft tissue mass

Head And Neck Eyes:
retinoblastoma (in some patients)

Skeletal Limbs:
painful tender mass at long bone metaphysis

Clinical features from OMIM:

259500

Drugs & Therapeutics for Osteogenic Sarcoma

Drugs for Osteogenic Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 381)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic Acid Approved Phase 4,Phase 2,Phase 3,Phase 1 118072-93-8 68740
2
Denosumab Approved Phase 4,Phase 3,Phase 2 615258-40-7
3
Lithium carbonate Approved Phase 4 554-13-2
4
Heparin Approved, Investigational Phase 4,Not Applicable 9005-49-6 46507594 772
5
Dalteparin Approved Phase 4,Not Applicable 9005-49-6
6
Enoxaparin Approved Phase 4 9005-49-6 772
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8 Bone Density Conservation Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
10 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
11 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
12 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1
13 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Central Nervous System Depressants Phase 4,Phase 3,Phase 1
20 Immunoglobulin G Phase 4,Phase 2
21 Cyclooxygenase Inhibitors Phase 4,Phase 2,Not Applicable
22 Tranquilizing Agents Phase 4,Phase 1
23 Antidepressive Agents Phase 4
24 Psychotropic Drugs Phase 4,Phase 1
25 Antimanic Agents Phase 4,Phase 1
26 Fibrinolytic Agents Phase 4,Not Applicable
27 Anticoagulants Phase 4,Not Applicable
28 calcium heparin Phase 4,Not Applicable
29 Heparin, Low-Molecular-Weight Phase 4,Not Applicable
30 Platelet Aggregation Inhibitors Phase 4
31 Antipyretics Phase 4
32
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 23214-92-8 31703
33
Ifosfamide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 3778-73-2 3690
34
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
35
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 1177-87-3
36
Gemcitabine Approved Phase 2, Phase 3,Phase 1,Not Applicable 95058-81-4 60750
37
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 114977-28-5 148124
38
Promethazine Approved, Investigational Phase 2, Phase 3 60-87-7 4927
39
Diphenhydramine Approved, Investigational Phase 2, Phase 3 147-24-0, 58-73-1 3100
40
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 50-02-2 5743
41
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
42
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 123774-72-1, 83869-56-1
43
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 460612 4053
44
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
45
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
46
Etoposide Approved Phase 3,Phase 1,Phase 2,Not Applicable 33419-42-0 36462
47
Dactinomycin Approved, Investigational Phase 3,Phase 2,Not Applicable 50-76-0 457193 2019
48
Mesna Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 3375-50-6 598
49
Cobalt Approved, Experimental Phase 3,Phase 1,Phase 2 7440-48-4 104729
50
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978

Interventional clinical trials:

(show top 50) (show all 500)
# Name Status NCT ID Phase Drugs
1 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
2 Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma Recruiting NCT03932071 Phase 4 Zoledronic Acid
3 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
4 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
5 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
6 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
7 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Unknown status NCT01987596 Phase 3
8 Study in Localized and Disseminated Ewing Sarcoma Unknown status NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
9 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
10 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
11 Non-invasive Focal Therapy for Osteoid Osteoma Unknown status NCT02302651 Phase 2, Phase 3
12 Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone Unknown status NCT03259152 Phase 3 Denosumab
13 ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma Completed NCT01459484 Phase 2, Phase 3 Mifamurtide arm
14 Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study Completed NCT00001217 Phase 3 pre-surgical chemotherapy
15 Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy Completed NCT02711007 Phase 2, Phase 3 apatinib
16 Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children Completed NCT00180908 Phase 3 Etoposide, Ifosfamide, Methotrexate;Doxorubicin, Methotrexate
17 Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma Completed NCT01176981 Phase 3 High Dose Methotrexate
18 Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma Completed NCT00002539 Phase 3 cisplatin;doxorubicin hydrochloride
19 Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma Completed NCT00003937 Phase 3 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate
20 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
21 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
22 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
23 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
24 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
25 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
26 Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Completed NCT02063022 Phase 3 Standard treatment (as per protocol ISG SSG III);Intensified chemotherapy
27 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
28 Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma Recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
29 Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas Recruiting NCT02923011 Phase 3
30 Zoledronic Acid Compared to Percutaneous Treatment in Osteoid Osteoma Recruiting NCT02739555 Phase 3 Acide Zoledronique MEDAC
31 Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone Recruiting NCT03295981 Phase 3 Zoledronic Acid
32 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Active, not recruiting NCT00134030 Phase 3 Cisplatin;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
33 Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer Active, not recruiting NCT01916317 Phase 3 0.5% lignocaine 60mM
34 Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Active, not recruiting NCT02856048 Phase 2, Phase 3 Triptorelin (GnRHa) + Chemotherapy
35 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
36 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Vincristine Sulfate
37 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate
38 Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma Terminated NCT00470223 Phase 3 cisplatin;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate;zoledronic acid
39 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
40 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
41 Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia Terminated NCT00127387 Phase 2, Phase 3 Enbrel
42 Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Withdrawn NCT01734863 Phase 3
43 Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma Withdrawn NCT00334867 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
44 Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma Unknown status NCT01216826 Phase 2 Everolimus
45 A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma Unknown status NCT01002092 Phase 2 Chemotherapy;Endostar
46 Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma Unknown status NCT00689195 Phase 1, Phase 2
47 Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study. Unknown status NCT03163381 Phase 2 Apatinib
48 Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity Unknown status NCT02273583 Phase 2 continuous oral cyclophosphamide and methotrexate
49 Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Unknown status NCT00026416 Phase 2 thalidomide
50 Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy Unknown status NCT00807261 Phase 2 Gemcitabine and Docetaxel

Search NIH Clinical Center for Osteogenic Sarcoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: osteosarcoma

Genetic Tests for Osteogenic Sarcoma

Genetic tests related to Osteogenic Sarcoma:

# Genetic test Affiliating Genes
1 Osteosarcoma 30 CHEK2 RB1 TP53

Anatomical Context for Osteogenic Sarcoma

MalaCards organs/tissues related to Osteogenic Sarcoma:

42
Bone, T Cells, Kidney, Brain, Testes, Prostate, Bone Marrow

The Foundational Model of Anatomy Ontology organs/tissues related to Osteogenic Sarcoma:

20
Bone

Publications for Osteogenic Sarcoma

Articles related to Osteogenic Sarcoma:

(show top 50) (show all 4211)
# Title Authors Year
1
Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Promotes Proliferation and Metastasis of Osteosarcoma Cells by Targeting c-Met and SOX4 via miR-34a/c-5p and miR-449a/b. ( 30793707 )
2019
2
Diagnostic evaluation and treatment of primary breast osteosarcoma: A case report. ( 31077474 )
2019
3
Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD and a targetable FN1-FGFR1 gene fusion. ( 31066955 )
2019
4
Successful Treatment of Osteosarcoma Without Methotrexate in a 13-Year-Old Boy With Down Syndrome. ( 29750745 )
2019
5
Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. ( 30880335 )
2019
6
Maternally expressed, paternally imprinted, embryonic non-coding RNA are expressed in osteosarcoma, Ewing sarcoma and spindle cell sarcoma. ( 30497804 )
2019
7
Treatment and survival of osteosarcoma and Ewing sarcoma of the skull: a SEER database analysis. ( 30578430 )
2019
8
Multimodal radiological imaging of collagenous fibroma arising from the subacromial region in a patient with osteosarcoma: A case report. ( 30847175 )
2019
9
Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor-β axis. ( 30894277 )
2019
10
Lymphocyte-monocyte ratio at day 14 of first cisplatin-doxorubicin chemotherapy is associated with treatment outcome of pediatric patients with localized osteosarcoma. ( 30304898 )
2019
11
Cytokine Expression in Canine Lymphoma, Osteosarcoma, Mammary Gland Tumour and Melanoma: Comparative Aspects. ( 30987001 )
2019
12
Antitumor effects of SB injection in canine osteosarcoma and melanoma cell lines. ( 30382494 )
2019
13
Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors. ( 30165126 )
2019
14
Osteoblastoma-like osteosarcoma: high-grade or low-grade osteosarcoma? ( 30152881 )
2019
15
Atypical "Sclerosing" Osteoblastic Neoplasm: A Tumor of Intermediate Biological Potential Between Usual Osteoblastoma and Conventional Osteosarcoma. ( 30807304 )
2019
16
Transformation of Ischial Osteoblastoma Into High-Grade Osteoblastoma-Like Osteosarcoma. ( 30810758 )
2019
17
Spontaneous expectoration of pulmonary metastases in a child with osteogenic sarcoma. ( 30637924 )
2019
18
Intradural osteogenic sarcoma in the lumbar spine. ( 30922531 )
2019
19
Metachronous extraskeletal (soft tissue) epithelioid osteogenic sarcoma: a case report. ( 31068214 )
2019
20
The Endocannabinoid/Endovanilloid System in Bone: From Osteoporosis to Osteosarcoma. ( 31003519 )
2019
21
Pediatric Osteosarcoma of Extremities: A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt. ( 30629005 )
2019
22
Educational Case: Pediatric Osteosarcoma. ( 30859126 )
2019
23
Clinical Prognostic Factors and Outcome in Pediatric Osteosarcoma: Effect of Delay in Local Control and Degree of Necrosis in a Multidisciplinary Setting in Lebanon. ( 30946633 )
2019
24
Curative-intent radiotherapy for pediatric osteosarcoma: The St. Jude experience. ( 31012273 )
2019
25
Long-term outcomes and prognostic factors of pulmonary metastasectomy for osteosarcoma and soft tissue sarcoma. ( 30806840 )
2019
26
Identification of co-expression modules and pathways correlated with osteosarcoma and its metastasis. ( 30849987 )
2019
27
MicroRNA-432 is downregulated in osteosarcoma and inhibits cell proliferation and invasion by directly targeting metastasis-associated in colon cancer-1. ( 30651881 )
2019
28
miR-142-5p suppresses proliferation and promotes apoptosis of human osteosarcoma cell line, HOS, by targeting PLA2G16 through the ERK1/2 signaling pathway. ( 30655907 )
2019
29
Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling. ( 30761524 )
2019
30
Modified total humeral replacement on unusual osteosarcoma of the humerus: A case report. ( 31039510 )
2019
31
Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers. ( 31040694 )
2019
32
miR-328-3p mediates the anti-tumor effect in osteosarcoma via directly targeting MMP-16. ( 31043859 )
2019
33
Fisetin activates Hippo pathway and JNK/ERK/AP-1 signaling to inhibit proliferation and induce apoptosis of human osteosarcoma cells via ZAK overexpression. ( 31044527 )
2019
34
Long noncoding RNA NEAT1 regulates the development of osteosarcoma through sponging miR-34a-5p to mediate HOXA13 expression as a competitive endogenous RNA. ( 31044561 )
2019
35
12b80 - Hydroxybisphosphonate linked doxorubicin: bone targeted strategy for treatment of osteosarcoma. ( 31045351 )
2019
36
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. ( 31047947 )
2019
37
A giant cell rich osteosarcoma of the proximal ulnar bone treated by elbow arthroplasty: A case report. ( 31048211 )
2019
38
Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1. ( 31050072 )
2019
39
Inhibitory effects of indirubin-3'-monoxime against human osteosarcoma. ( 31050877 )
2019
40
Osteosarcoma and second malignant neoplasms: a case series. ( 31054046 )
2019
41
Clinical importance of S100A9 in osteosarcoma development and as a diagnostic marker and therapeutic target. ( 31055998 )
2019
42
Upregulation of miR-214 Induced Radioresistance of Osteosarcoma by Targeting PHLDA2 via PI3K/Akt Signaling. ( 31058093 )
2019
43
Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? ( 31058424 )
2019
44
Tranilast enhances the effect of anticancer agents in osteosarcoma. ( 31059083 )
2019
45
Primary Osteosarcoma of the Breast. ( 31059400 )
2019
46
Glaucocalyxin A reverses EMT and TGF-β1-induced EMT by inhibiting TGF-β1/Smad2/3 signaling pathway in osteosarcoma. ( 31059706 )
2019
47
Reverse shoulder arthroplasty after failed megaprosthesis for osteosarcoma of the proximal humerus: A case report and review of literature. ( 31061583 )
2019
48
Dysregulated circRNA_100876 suppresses proliferation of osteosarcoma cancer cells by targeting microRNA-136. ( 31069828 )
2019
49
LncRNA LINC-PINT Inhibits Cancer Cell Proliferation, Invasion, and Migration in Osteosarcoma by Downregulating miRNA-21. ( 31070482 )
2019
50
MiR-217 Inhibits Proliferation, Migration, and Invasion by Targeting SIRT1 in Osteosarcoma. ( 31070483 )
2019

Variations for Osteogenic Sarcoma

ClinVar genetic disease variations for Osteogenic Sarcoma:

6 (show top 50) (show all 130)
# Gene Variation Type Significance SNP ID Assembly Location
1 CHEK2 NM_007194.4(CHEK2): c.254C> T (p.Pro85Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs17883862 GRCh37 Chromosome 22, 29130456: 29130456
2 CHEK2 NM_007194.4(CHEK2): c.254C> T (p.Pro85Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs17883862 GRCh38 Chromosome 22, 28734468: 28734468
3 CHEK2 NM_007194.4(CHEK2): c.49G> T (p.Ala17Ser) single nucleotide variant Pathogenic rs137853008 GRCh37 Chromosome 22, 29130661: 29130661
4 CHEK2 NM_007194.4(CHEK2): c.49G> T (p.Ala17Ser) single nucleotide variant Pathogenic rs137853008 GRCh38 Chromosome 22, 28734673: 28734673
5 CHEK2 NM_007194.4(CHEK2): c.542G> A (p.Arg181His) single nucleotide variant Uncertain significance rs121908701 GRCh37 Chromosome 22, 29121015: 29121015
6 CHEK2 NM_007194.4(CHEK2): c.542G> A (p.Arg181His) single nucleotide variant Uncertain significance rs121908701 GRCh38 Chromosome 22, 28725027: 28725027
7 CHEK2 NM_007194.4(CHEK2): c.715G> A (p.Glu239Lys) single nucleotide variant Uncertain significance rs121908702 GRCh37 Chromosome 22, 29107974: 29107974
8 CHEK2 NM_007194.4(CHEK2): c.715G> A (p.Glu239Lys) single nucleotide variant Uncertain significance rs121908702 GRCh38 Chromosome 22, 28711986: 28711986
9 CHEK2 NM_007194.4(CHEK2): c.1283C> T (p.Ser428Phe) single nucleotide variant risk factor rs137853011 GRCh37 Chromosome 22, 29091207: 29091207
10 CHEK2 NM_007194.4(CHEK2): c.1283C> T (p.Ser428Phe) single nucleotide variant risk factor rs137853011 GRCh38 Chromosome 22, 28695219: 28695219
11 ATRX NM_000489.4(ATRX): c.7156C> T (p.Arg2386Ter) single nucleotide variant Pathogenic rs122445099 GRCh37 Chromosome X, 76776310: 76776310
12 ATRX NM_000489.4(ATRX): c.7156C> T (p.Arg2386Ter) single nucleotide variant Pathogenic rs122445099 GRCh38 Chromosome X, 77520832: 77520832
13 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
14 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
15 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
16 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
17 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
18 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
19 TP53 NM_000546.5(TP53): c.524G> A (p.Arg175His) single nucleotide variant Pathogenic rs28934578 GRCh37 Chromosome 17, 7578406: 7578406
20 TP53 NM_000546.5(TP53): c.524G> A (p.Arg175His) single nucleotide variant Pathogenic rs28934578 GRCh38 Chromosome 17, 7675088: 7675088
21 TP53 NM_000546.5(TP53): c.475_481dupGCCATGG (p.Ala161Glyfs) duplication Pathogenic rs863223301 GRCh38 Chromosome 17, 7675131: 7675137
22 TP53 NM_000546.5(TP53): c.475_481dupGCCATGG (p.Ala161Glyfs) duplication Pathogenic rs863223301 GRCh37 Chromosome 17, 7578449: 7578455
23 RB1 NM_000321.2(RB1): c.1981C> T (p.Arg661Trp) single nucleotide variant Pathogenic rs137853294 GRCh37 Chromosome 13, 49033844: 49033844
24 RB1 NM_000321.2(RB1): c.1981C> T (p.Arg661Trp) single nucleotide variant Pathogenic rs137853294 GRCh38 Chromosome 13, 48459708: 48459708
25 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
26 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
27 RB1 NM_000321.2(RB1): c.1215+1G> A single nucleotide variant Pathogenic rs587776783 GRCh37 Chromosome 13, 48947629: 48947629
28 RB1 NM_000321.2(RB1): c.1215+1G> A single nucleotide variant Pathogenic rs587776783 GRCh38 Chromosome 13, 48373493: 48373493
29 CHEK2 NM_007194.4(CHEK2): c.1336A> G (p.Asn446Asp) single nucleotide variant Uncertain significance rs121908705 GRCh37 Chromosome 22, 29091154: 29091154
30 CHEK2 NM_007194.4(CHEK2): c.1336A> G (p.Asn446Asp) single nucleotide variant Uncertain significance rs121908705 GRCh38 Chromosome 22, 28695166: 28695166
31 TP53 NM_000546.5(TP53): c.466C> T (p.Arg156Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs563378859 GRCh37 Chromosome 17, 7578464: 7578464
32 TP53 NM_000546.5(TP53): c.466C> T (p.Arg156Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs563378859 GRCh38 Chromosome 17, 7675146: 7675146
33 TP53 NM_000546.5(TP53): c.847C> T (p.Arg283Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs149633775 GRCh37 Chromosome 17, 7577091: 7577091
34 TP53 NM_000546.5(TP53): c.847C> T (p.Arg283Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs149633775 GRCh38 Chromosome 17, 7673773: 7673773
35 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh37 Chromosome 22, 29091857: 29091857
36 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh38 Chromosome 22, 28695869: 28695869
37 CHEK2 NM_007194.4(CHEK2): c.1111C> T (p.His371Tyr) single nucleotide variant Uncertain significance rs531398630 GRCh37 Chromosome 22, 29091846: 29091846
38 CHEK2 NM_007194.4(CHEK2): c.1111C> T (p.His371Tyr) single nucleotide variant Uncertain significance rs531398630 GRCh38 Chromosome 22, 28695858: 28695858
39 CHEK2 NM_007194.4(CHEK2): c.1133C> T (p.Thr378Ile) single nucleotide variant Uncertain significance rs587780167 GRCh37 Chromosome 22, 29091824: 29091824
40 CHEK2 NM_007194.4(CHEK2): c.1133C> T (p.Thr378Ile) single nucleotide variant Uncertain significance rs587780167 GRCh38 Chromosome 22, 28695836: 28695836
41 CHEK2 NM_007194.4(CHEK2): c.1215C> A (p.Asn405Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs587780171 GRCh37 Chromosome 22, 29091742: 29091742
42 CHEK2 NM_007194.4(CHEK2): c.1215C> A (p.Asn405Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs587780171 GRCh38 Chromosome 22, 28695754: 28695754
43 CHEK2 NM_007194.4(CHEK2): c.1270T> C (p.Tyr424His) single nucleotide variant Conflicting interpretations of pathogenicity rs139366548 GRCh37 Chromosome 22, 29091220: 29091220
44 CHEK2 NM_007194.4(CHEK2): c.1270T> C (p.Tyr424His) single nucleotide variant Conflicting interpretations of pathogenicity rs139366548 GRCh38 Chromosome 22, 28695232: 28695232
45 CHEK2 NM_007194.4(CHEK2): c.1312G> T (p.Asp438Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs200050883 GRCh37 Chromosome 22, 29091178: 29091178
46 CHEK2 NM_007194.4(CHEK2): c.1312G> T (p.Asp438Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs200050883 GRCh38 Chromosome 22, 28695190: 28695190
47 CHEK2 NM_007194.4(CHEK2): c.1420C> T (p.Arg474Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs540635787 GRCh37 Chromosome 22, 29090061: 29090061
48 CHEK2 NM_007194.4(CHEK2): c.1420C> T (p.Arg474Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs540635787 GRCh38 Chromosome 22, 28694073: 28694073
49 CHEK2 NM_007194.4(CHEK2): c.1525C> T (p.Pro509Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs587780179 GRCh37 Chromosome 22, 29085140: 29085140
50 CHEK2 NM_007194.4(CHEK2): c.1525C> T (p.Pro509Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs587780179 GRCh38 Chromosome 22, 28689152: 28689152

Cosmic variations for Osteogenic Sarcoma:

9 (show all 21)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6921292 SMARCA4 bone,NS,osteosarcoma,osteoblastic c.2728A>G p.T910A 19:11021836-11021836 0
2 COSM6912846 RYBP bone,NS,osteosarcoma,chondroblastic c.699+1G>A p.? 3:72379039-72379039 0
3 COSM2804274 RPTOR bone,NS,osteosarcoma,chondroblastic c.2911G>A p.V971I 17:80925472-80925472 0
4 COSM866 RB1 bone,NS,osteosarcoma,osteoblastic c.1399C>T p.R467* 13:48380062-48380062 0
5 COSM1034 RB1 bone,NS,osteosarcoma,chondroblastic c.1499-1G>T p.? 13:48381246-48381246 0
6 COSM6932882 PTCH1 bone,NS,osteosarcoma,chondroblastic c.2183C>T p.T728M 9:95468818-95468818 0
7 COSM6912848 PIK3CB bone,NS,osteosarcoma,chondroblastic c.1064C>G p.A355G 3:138714706-138714706 0
8 COSM302646 KMT2D bone,NS,osteosarcoma,chondroblastic c.15208C>T p.R5070* 12:49024612-49024612 0
9 COSM4591270 KMT2C bone,NS,osteosarcoma,chondroblastic c.2512G>A p.G838S 7:152247922-152247922 0
10 COSM1179669 KMT2C bone,NS,osteosarcoma,chondroblastic c.943G>A p.G315S 7:152273774-152273774 0
11 COSM6506545 KMT2C bone,NS,osteosarcoma,chondroblastic c.2468T>C p.I823T 7:152247966-152247966 0
12 COSM27895 GNAS bone,NS,osteosarcoma,parosteal c.602G>A p.R201H 20:58909366-58909366 0
13 COSM27887 GNAS bone,NS,osteosarcoma,parosteal c.601C>T p.R201C 20:58909365-58909365 0
14 COSM6914869 APC bone,NS,osteosarcoma,chondroblastic c.6517A>G p.K2173E 5:112842111-112842111 0
15 COSM6932881 bone,NS,osteosarcoma,chondroblastic c.2183C>T p.T728M 9:95468818-95468818 0
16 COSM6932883 bone,NS,osteosarcoma,chondroblastic c.2180C>T p.T727M 9:95468818-95468818 0
17 COSM123397 bone,NS,osteosarcoma,chondroblastic c.2530C>T p.R844C 20:58909365-58909365 0
18 COSM6912847 bone,NS,osteosarcoma,chondroblastic c.699+1G>A p.? 3:72379039-72379039 0
19 COSM6932884 bone,NS,osteosarcoma,chondroblastic c.2180C>T p.T727M 9:95468818-95468818 0
20 COSM302647 bone,NS,osteosarcoma,chondroblastic c.16018C>T p.R5340* 12:49024612-49024612 0
21 COSM6921291 bone,NS,osteosarcoma,osteoblastic c.2728A>G p.T910A 19:11021836-11021836 0

Copy number variations for Osteogenic Sarcoma from CNVD:

7 (show top 50) (show all 688)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17390 1 142600000 150300000 Gain Osteosarcoma
2 17391 1 142600000 155000000 Amplification Osteosarcoma
3 39243 10 112373403 112374403 Gain Osteosarcoma
4 39244 10 112373452 112374452 Loss Osteosarcoma
5 41292 10 15522819 15523819 Loss Osteosarcoma
6 41294 10 15581536 15582536 Loss Osteosarcoma
7 46318 10 80680600 80681600 Loss Osteosarcoma
8 46347 10 80806585 80807585 Loss Osteosarcoma
9 58796 11 69623478 69623778 Gain Osteosarcoma
10 58827 11 69805619 69805919 Loss Osteosarcoma
11 60316 11 85062165 85063165 Gain Osteosarcoma
12 60323 11 85134471 85135471 Gain Osteosarcoma
13 62537 12 10955611 10956611 Gain Osteosarcoma
14 62568 12 10980072 10981072 Gain Osteosarcoma
15 62603 12 11027103 11028103 Loss Osteosarcoma
16 63038 12 11366981 11367981 Gain Osteosarcoma
17 63258 12 11668570 11669570 Gain Osteosarcoma
18 63272 12 11686468 11687468 Loss Osteosarcoma
19 64267 12 12569624 12570624 Loss Osteosarcoma
20 64268 12 12573054 12574054 Loss Osteosarcoma
21 64280 12 12586928 12587928 Gain Osteosarcoma
22 64287 12 12597865 12598865 Loss Osteosarcoma
23 64343 12 12687540 12688540 Gain Osteosarcoma
24 64577 12 12982393 12983393 Gain Osteosarcoma
25 64986 12 14117741 14118741 Loss Osteosarcoma
26 64996 12 14185562 14186562 Gain Osteosarcoma
27 64998 12 14245323 14246323 Gain Osteosarcoma
28 65344 12 16046949 16047949 Gain Osteosarcoma
29 65345 12 16049923 16050923 Loss Osteosarcoma
30 65347 12 16051037 16052037 Gain Osteosarcoma
31 65348 12 16051062 16052062 Loss Osteosarcoma
32 65349 12 16054806 16055806 Gain Osteosarcoma
33 65384 12 16430865 16431865 Gain Osteosarcoma
34 65385 12 16433142 16434142 Loss Osteosarcoma
35 65386 12 16436484 16437484 Gain Osteosarcoma
36 65391 12 16463017 16464017 Gain Osteosarcoma
37 65392 12 16466398 16467398 Gain Osteosarcoma
38 65400 12 16603247 16604247 Loss Osteosarcoma
39 65436 12 17462418 17463418 Gain Osteosarcoma
40 65437 12 17462804 17463804 Loss Osteosarcoma
41 65493 12 1815281 1816281 Loss Osteosarcoma
42 65649 12 20337069 20338069 Gain Osteosarcoma
43 65959 12 23459482 23460482 Loss Osteosarcoma
44 65979 12 23822360 23823360 Loss Osteosarcoma
45 66478 12 29963884 29964884 Loss Osteosarcoma
46 66480 12 29986214 29987214 Gain Osteosarcoma
47 66482 12 30002256 30003256 Loss Osteosarcoma
48 66483 12 30014548 30015548 Loss Osteosarcoma
49 66485 12 30029899 30030899 Loss Osteosarcoma
50 67171 12 37173408 37174408 Loss Osteosarcoma

Expression for Osteogenic Sarcoma

Search GEO for disease gene expression data for Osteogenic Sarcoma.

Pathways for Osteogenic Sarcoma

GO Terms for Osteogenic Sarcoma

Cellular components related to Osteogenic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 8.92 ATRX CHEK2 RB1 TP53

Biological processes related to Osteogenic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.8 AKT1 CHEK2 RB1 SOX4 TP53
2 cellular response to hypoxia GO:0071456 9.61 AKT1 MIR140 TP53
3 DNA damage response, signal transduction by p53 class mediator GO:0030330 9.37 ATRX TP53
4 striated muscle cell differentiation GO:0051146 9.32 AKT1 RB1
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.26 CHEK2 TP53
6 replicative senescence GO:0090399 9.16 CHEK2 TP53
7 regulation of signal transduction by p53 class mediator GO:1901796 9.13 AKT1 CHEK2 TP53
8 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 8.8 CHEK2 SOX4 TP53

Sources for Osteogenic Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....